LU92239I2 - Vésicules de membrane externe (VME) du groupe B deNeisseria meningitidis - Google Patents

Vésicules de membrane externe (VME) du groupe B deNeisseria meningitidis

Info

Publication number
LU92239I2
LU92239I2 LU92239C LU92239C LU92239I2 LU 92239 I2 LU92239 I2 LU 92239I2 LU 92239 C LU92239 C LU 92239C LU 92239 C LU92239 C LU 92239C LU 92239 I2 LU92239 I2 LU 92239I2
Authority
LU
Luxembourg
Prior art keywords
outer membrane
pellet
membrane vesicles
collecting
detergent
Prior art date
Application number
LU92239C
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9943238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92239(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LU92239I2 publication Critical patent/LU92239I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
LU92239C 2002-08-30 2013-07-04 Vésicules de membrane externe (VME) du groupe B deNeisseria meningitidis LU92239I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0220194.5A GB0220194D0 (en) 2002-08-30 2002-08-30 Improved vesicles

Publications (1)

Publication Number Publication Date
LU92239I2 true LU92239I2 (fr) 2013-09-04

Family

ID=9943238

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92239C LU92239I2 (fr) 2002-08-30 2013-07-04 Vésicules de membrane externe (VME) du groupe B deNeisseria meningitidis

Country Status (21)

Country Link
US (2) US20060166344A1 (fr)
EP (5) EP1534326B1 (fr)
JP (3) JP2006503822A (fr)
CN (2) CN102188700A (fr)
AT (1) ATE366117T1 (fr)
AU (1) AU2003263534B2 (fr)
BR (1) BRPI0314094A8 (fr)
CA (1) CA2497165C (fr)
CY (3) CY1107737T1 (fr)
DE (1) DE60314756T2 (fr)
DK (3) DK1864679T3 (fr)
ES (4) ES2289351T3 (fr)
FR (1) FR13C0046I2 (fr)
GB (1) GB0220194D0 (fr)
LU (1) LU92239I2 (fr)
MX (1) MXPA05002316A (fr)
NZ (1) NZ538673A (fr)
PT (3) PT1534326E (fr)
RU (1) RU2325184C2 (fr)
SI (2) SI2258389T1 (fr)
WO (1) WO2004019977A2 (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE446368T1 (de) * 1998-01-14 2009-11-15 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
EP1179072A2 (fr) 1999-05-19 2002-02-13 Chiron S.P.A. Compositions a base de combinaisons de neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CU23377A1 (es) * 2003-11-04 2009-05-28 Ct De Ingenieria Genetica Y Biotecnologia Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes
GB0416120D0 (en) 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's
CA2576280A1 (fr) 2004-08-13 2006-02-16 Barry J. Marshall Systeme liberation a base helicobacter pylori
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
JP2008530245A (ja) * 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
WO2006123164A2 (fr) * 2005-05-19 2006-11-23 The Edward Jenner Institute For Vaccine Research Procedes de traitement et de prevention des infections
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
HRP20120433T1 (en) 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CN104548082A (zh) 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
US9266942B2 (en) * 2009-04-30 2016-02-23 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHbp) and methods of use
CA2765112A1 (fr) 2009-06-10 2010-12-16 Novartis Ag Vaccins contenant de la benzonaphtyridine
WO2011022228A2 (fr) * 2009-08-20 2011-02-24 Srisuda Dhamwichukorn Appareil et procédé de dislocation et d'extraction améliorés de matières intracellulaires à partir de cellules microbiennes
WO2011024072A2 (fr) 2009-08-27 2011-03-03 Novartis Ag Polypeptides hybrides contenant des séquences fhbp à méningocoques
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
WO2011027971A2 (fr) 2009-09-01 2011-03-10 주식회사이언메딕스 Vésicules extracellulaires dérivées de la flore intestinale, et procédé de recherche d'un modèle de maladie, d'un vaccin et d'un médicament candidat, et de diagnostic utilisant ce dernier
WO2011027956A2 (fr) 2009-09-04 2011-03-10 주식회사이언메딕스 Vésicules extracellulaires issues de bactéries à gram positif, et modèle de maladie utilisant celles-ci
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
CA2779816A1 (fr) 2009-10-27 2011-05-05 Novartis Ag Polypeptides fhbp meningococciques modifies
WO2011057148A1 (fr) 2009-11-05 2011-05-12 Irm Llc Composés et compositions permettant de moduler l'activité des tlr-7
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
WO2012020326A1 (fr) 2010-03-18 2012-02-16 Novartis Ag Vaccins adjuvantés contre le méningocoque de sérogroupe b
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
US9066971B2 (en) 2010-07-01 2015-06-30 Postech Academy-Industry Foundation Method for treating and diagnosing cancer by using cell-derived microvesicles
CA2808975C (fr) 2010-08-23 2018-10-30 Wyeth Llc Formulations stables des antigenes rlp2086 de neisseria meningitidis
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
CA2810971C (fr) 2010-09-10 2020-11-03 Novartis Ag Developpements apportes a des vesicules membranaires externes meningococciques
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
EP2729167B1 (fr) * 2011-07-07 2018-03-14 De Staat der Nederlanden, vert. door de Minister van VWS Procédé de production sans détergent de vésicules de membrane externe de bactéries gram-négatives
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
WO2013132040A2 (fr) 2012-03-08 2013-09-12 Novartis Ag Dosage de puissance in vitro pour des vaccins méningococciques à base de protéine
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (fr) 2012-03-09 2018-01-09 Pfizer Inc. Compositions de neisseria meningitidis et procedes associes
US9808517B2 (en) 2012-04-06 2017-11-07 Cornell University Subunit vaccine delivery platform for robust humoral and cellular immune responses
ES2847923T3 (es) 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
CN104736563A (zh) 2012-07-27 2015-06-24 国家健康与医学研究院 Cd147作为受体用于脑膜炎球菌至血管内皮的菌毛介导的粘附
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
BR112015018877A2 (pt) 2013-02-07 2017-08-22 Externautics Spa Método para preparar uma composição farmacêutica, e, composição farmacêutica imunogênica
CA2903716C (fr) 2013-03-08 2019-04-09 Pfizer Inc. Polypeptides immunogenes de fusion
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CN106661092B (zh) 2014-02-28 2021-07-06 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
US11066453B2 (en) 2015-05-18 2021-07-20 Biomvis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
CA3004924A1 (fr) * 2015-11-10 2017-05-18 Ohio State Innovation Foundation Methodes et compositions associees a une affinite humorale acceleree
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
US11447738B2 (en) 2016-10-28 2022-09-20 Vedanta Biosciences, Inc. Methods and compositions for preserving bacteria
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
CN110891599A (zh) * 2017-03-31 2020-03-17 印度医学研究理事会 基于来自伤寒样沙门菌物种的两种不同菌株的外膜囊泡的肠热疫苗
AU2018330322A1 (en) 2017-09-08 2020-03-19 Evelo Biosciences, Inc. Bacterial extracellular vesicles
US10793865B2 (en) 2018-06-05 2020-10-06 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Transferrable mechanism of generating inducible, BAR domain protein-mediated bacterial outer membrane extensions
EP3607967A1 (fr) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Polypeptides modifiés du méningocoque fhbp
US12128094B2 (en) 2018-11-06 2024-10-29 Glaxosmithkline Biologicals Sa Immunogenic compositions comprising OMVs, an acellular pertussis antigen, a tetanus toxoid and a diphtheria toxoid
JP2022520999A (ja) * 2019-02-22 2022-04-04 エヴェロ バイオサイエンシズ，インコーポレーテッド 細菌の膜調製物
WO2021031270A1 (fr) * 2019-08-22 2021-02-25 四川大学 Vésicules de membrane bactérienne, et système de séparation et de préparation et méthode associée
CN110563829B (zh) * 2019-09-17 2021-03-26 中国人民解放军国防科技大学 用于调控脂质体囊泡行为、功能的反光蛋白体系及其应用
CA3155669A1 (fr) 2019-09-27 2021-04-01 Pfizer Inc. Compositions de neisseria meningitidis et methodes associees
EP3799884A1 (fr) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Compositions immunogènes
IL300922A (en) 2020-09-11 2023-04-01 Glaxosmithkline Biologicals Sa outer membrane vesicles
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
WO2023097652A1 (fr) * 2021-12-03 2023-06-08 National Center For Nanoscience And Technology Cellule modifiée et son application
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
AU640118B2 (en) 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
CA2006700A1 (fr) 1989-01-17 1990-07-17 Antonello Pessi Peptides synthetiques et leur utilisation comme porteurs universels pour la preparation de conjugats immunogenes convenant a la mise au point de vaccins synthetiques
WO1990014837A1 (fr) 1989-05-25 1990-12-13 Chiron Corporation Composition d'adjuvant comprenant une emulsion de gouttelettes d'huile d'une taille inferieure au micron
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
US5993826A (en) 1993-03-02 1999-11-30 Board Of Regents, The University Of Texas Methods and compositions relating to useful antigens of moraxella catarrhalis
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FR2692592B1 (fr) * 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
DK0624376T3 (da) 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0710118T3 (da) * 1994-04-20 1999-08-09 Us Army Vaccine mod infektioner med gram-negative bakterier
JPH10502365A (ja) 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクタータンパク質およびワクチン
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) * 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
BR9609882A (pt) 1995-08-04 1999-07-27 Univ Guelph Vacina processos para preparar a mesma para tratar uma doença infecciosa para inserir uma molécula de ácido nucleico em uma célula de marcaç o para administrar um agente terapêutico a um hospedeiro e para triar um antígeno imunogênico de um patógeno uso de uma vesícula de membrana composição farmacêutica sistema de liberação de drogas e vesícula de membrana
EP0909323B1 (fr) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Bacterioferritine de helicobacter pilori
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
WO1998016247A1 (fr) 1996-10-11 1998-04-23 The Regents Of The University Of California Conjugues polynucleotide immunostimulateur/molecule immunomodulatrice
ES2195317T3 (es) 1997-01-30 2003-12-01 Chiron Corp Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias.
CA2281838A1 (fr) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Utilisation d'acides nucleiques contenant des dinucleotides cpg non methyles dans le traitement des troubles associes aux lipopolysaccharides
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (fr) 1997-05-20 2007-08-22 Ottawa Health Research Institute Procedes de preparation de constructions d'acides nucleiques
WO1998055609A1 (fr) 1997-06-06 1998-12-10 The Regents Of The University Of California Inhibiteurs de l'activite de sequences immunostimulatrices de l'adn
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
JP2001510169A (ja) * 1997-07-17 2001-07-31 ノース アメリカン ワクチン， インコーポレイテッド Ｂ型髄膜炎菌性ポーリンおよびＨ．ｉｎｆｌｕｅｎｚａｅ多糖体を含む免疫原性結合体
DE69738472T2 (de) 1997-08-21 2009-01-02 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Neue mutanten der gram-negativen mukosalen bakterien und ihre verwendung als impfstoffe
EP1279401B1 (fr) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Emulsions du type huile-dans-l'eau contenant des saponines
BR9813930A (pt) 1997-11-06 2006-12-19 Chiron Spa antìgeno neisserial
KR20010032336A (ko) 1997-11-21 2001-04-16 브랑디 빠스깔 클라미디아 뉴모니아 게놈 서열과 폴리펩티드, 이의 단편및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
KR100760221B1 (ko) 1997-11-28 2007-10-30 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
ATE446368T1 (de) 1998-01-14 2009-11-15 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
BR9914374A (pt) * 1998-10-09 2002-09-17 Chiron Corp Sequências genÈmicas de neisseria e métodos para seu uso
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
EP1133572A4 (fr) 1998-11-12 2005-06-15 Univ California Sequence genomique de chlamydia pneumoniae
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
ATE413188T1 (de) * 1999-02-05 2008-11-15 Merck & Co Inc Menschliche papillomavirus impfstoff- formulierungen
US7081244B2 (en) * 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
DK1154791T3 (da) 1999-02-22 2008-06-16 Health Prot Agency Neisseria-vaccinesammensætninger og fremgangsmåder
EP1154793B1 (fr) 1999-02-26 2010-09-15 Novartis Vaccines and Diagnostics, Inc. Utilisation de systemes bioadhesifs et d'adjuvants pour l'administration mucosale d'antigenes
CA2366152A1 (fr) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccin
US6245568B1 (en) * 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
WO2000061761A2 (fr) 1999-04-09 2000-10-19 Techlab, Inc. Support proteique recombinant de la toxine a pour vaccins conjugues polysaccharides
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
AUPQ005499A0 (en) * 1999-04-30 1999-05-27 Townsend, Roy Leslie Printing process
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
EP1179072A2 (fr) 1999-05-19 2002-02-13 Chiron S.P.A. Compositions a base de combinaisons de neisseria
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
IL148671A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
HK1049106A1 (zh) 1999-09-24 2003-05-02 Smithkline Beecham Biologicals S.A. 聚氧化乙烯山梨糖酯和octooxynol的聯用做為佐劑和其在疫苗中的用途
WO2001034642A2 (fr) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Commande de la synthese de membrane de neisseria
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0007433D0 (en) * 2000-03-27 2000-05-17 Microbiological Res Authority Recombinant transferrin binding proteins
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
GB0017149D0 (en) 2000-07-12 2000-08-30 Chiron Spa Helicobacter pylori mutants
MXPA03000822A (es) * 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2002026212A2 (fr) 2000-09-28 2002-04-04 Chiron Corporation Compositions de microparticules et procede de fabrication desdites compositions
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
GB0103171D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CN100350972C (zh) 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
CN1674933B (zh) * 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物

Also Published As

Publication number Publication date
JP2006503822A (ja) 2006-02-02
RU2325184C2 (ru) 2008-05-27
ATE366117T1 (de) 2007-07-15
DE60314756T2 (de) 2008-03-06
ES2483592T3 (es) 2014-08-06
BR0314094A (pt) 2005-11-16
FR13C0046I2 (fr) 2014-05-16
DK2258389T3 (da) 2013-08-26
US20150258188A1 (en) 2015-09-17
CN102188700A (zh) 2011-09-21
DE60314756D1 (de) 2007-08-16
EP2258390A1 (fr) 2010-12-08
BRPI0314094A8 (pt) 2018-04-03
JP5808358B2 (ja) 2015-11-10
EP1534326A2 (fr) 2005-06-01
DK1864679T3 (da) 2014-08-25
WO2004019977A2 (fr) 2004-03-11
FR13C0046I1 (fr) 2013-09-06
WO2004019977A3 (fr) 2004-07-15
CN1688334A (zh) 2005-10-26
CY1107737T1 (el) 2013-04-18
EP1534326B1 (fr) 2007-07-04
NZ538673A (en) 2008-04-30
AU2003263534A1 (en) 2004-03-19
DK1534326T3 (da) 2007-10-22
US20060166344A1 (en) 2006-07-27
EP2258388B1 (fr) 2014-08-13
PT1534326E (pt) 2007-10-17
ES2289351T3 (es) 2008-02-01
GB0220194D0 (en) 2002-10-09
EP1864679A3 (fr) 2008-04-02
JP2013139471A (ja) 2013-07-18
CA2497165C (fr) 2015-10-20
PT2258389E (pt) 2013-08-22
EP2258388A1 (fr) 2010-12-08
EP2258389A1 (fr) 2010-12-08
MXPA05002316A (es) 2005-06-08
PT1864679E (pt) 2014-09-25
JP2010150287A (ja) 2010-07-08
RU2005108994A (ru) 2006-02-10
SI2258389T1 (sl) 2013-07-31
SI1864679T1 (sl) 2014-10-30
EP1864679A2 (fr) 2007-12-12
ES2520392T3 (es) 2014-11-11
CY1114570T1 (el) 2017-01-25
CY1115777T1 (el) 2017-01-25
CA2497165A1 (fr) 2004-03-11
ES2423019T3 (es) 2013-09-17
AU2003263534B2 (en) 2010-08-05
EP2258389B1 (fr) 2013-06-05
EP1864679B1 (fr) 2014-06-18

Similar Documents

Publication Publication Date Title
DK1534326T3 (da) Bakteriel ydre membran-vesikler
JP2006503822A5 (fr)
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
DE60045034D1 (de) Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
NO20055817L (no) Apparat og fremgangsmate for behandling av injeksjonsfluid.
MY149398A (en) Multivalent pcv2 immunogenic compositions and methods of producing such compositions
CN104073537A (zh) 一种利用复合蛋白酶制备活性胶原蛋白的方法
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
CO5221126A1 (es) Metodo parta la preparacion de ingredientes alimenticios proteinicos de soya e ingredientes asi obtenidos
CN105131139B (zh) 一种肺炎链球菌荚膜多糖的纯化方法
DK71686A (da) Vaccine mod sygdomme foraarsaget af mikroorganismer, saasom mycoplasmaer, dens fremstilling og mikroorganisme-membraner som aktivt princip
Fan et al. rgpA DNA vaccine induces antibody response and prevents alveolar bone loss in experimental peri‐implantitis
ATE356633T1 (de) Vakzin für einen nicht typisierbaren haemophilus influenzae stamm
CH662056A5 (fr) Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies.
WO2002043651A3 (fr) Methodes d'utilisation de lymphocytes t mis en culture et n'induisant pas de reaction du greffon contre l'hote (gvhd) pour traiter des maladies
WO2024149109A1 (fr) Procédé de détoxification de la toxine pertussique et vaccin combiné contre la diphtérie, le tétanos et la coqueluche acellulaire
CN1279978C (zh) 博代氏杆菌所产皮肤坏死毒素和类毒素的纯化方法
AU2003303319A1 (en) Woodworking method and device
CN118598936A (zh) 水解角蛋白的制备工艺及其离心过滤装置
CN101412988A (zh) 孔雀石绿等三苯基甲烷类染料降解酶TpmD的制备方法
CN120310873A (zh) 一种抗衰抗氧化复合肽的制备方法和应用
CN116139329A (zh) 胎盘来源的基质凝胶及其制备方法
HYUN et al. Five Cases of Laser Goniopuncture after Deep Sclerectomy with Collagen implant
Liang et al. New Protocol to Treat Corneal Ulcer: 2 Years Retrospective Experience
ZHANG et al. Maxilla reconstruction with the free iliac osteomuscular flap and simultaneous osseointegrated implant embeding